GENE ONLINE|News &
Adaptimmune Therapeutics Breaks Rough Patch With New Multibillion-Dollar Collaboration
The shares of the UK-based biopharmaceutical Adaptimmune Therapeutics have had a rough year, with its stock down more than 35% between the beginning of January and mid-August of this year. In comparison, the SP500 index was up more than 20% at the same time.
On September 7th, UK-based biopharmaceutical, Adaptimmune's stock jumped almost 29% following the news that it has signed a collaboration deal worth up to $3 billion with Genentech.
As part of the deal, Adaptimmune will receive $150 million in cash upfront, $150 million more over the next five years, and developmental, regulatory, and commercial milestones potentially worth more than $3 billion. In addition, the company will receive royalties from the products they develop.
On September 7th, UK-based biopharmaceutical, Adaptimmune's stock jumped almost 29% following the news that it has signed a collaboration deal worth up to $3 billion with Genentech.
As part of the deal, Adaptimmune will receive $150 million in cash upfront, $150 million more over the next five years, and developmental, regulatory, and commercial milestones potentially worth more than $3 billion. In addition, the company will receive royalties from the products they develop.
GO Prime with only $1.49 now
LATEST
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
